Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Scandion Oncology
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==== SCO-101 works in synergy with nab-paclitaxel ==== Preclinical data presented by Scandion Oncology at the British Association for Cancer Research (BACR) in September 2021 demonstrate the potential of SCO-101 in combination with nab-paclitaxel (Exhibit 7). In these mouse model data, a paclitaxel/SCO-101 combination demonstrated a 63% reduction in tumour volume compared to control, and paclitaxel alone reduced volume by 28%. In Edison Investment Research's view, these preclinical data support the rationale for the combination of SCO-101 and nab-paclitaxel with gemcitabine in the treatment of PC. Nevertheless, Edison Investment Research notes that interpretation of preclinical results is not a reliable indicator of clinical utility. '''Exhibit 7: Preclinical SCO-101 data in combination with paclitaxel'''<ref>Source: Scandion Oncology BACR presentation September 2021.</ref> [[File:Image8-d2f0ab9ac32701491636345b4497b7bb.png|600px]]
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)